Events

Retiro De Equipo O Alerta De Seguridad para OSSEOTITE® 2 Certain® PREVAIL® endosteal dental implant 5 X 4.1 X 11.5 mm with reference no. XIIOS5411 and lot no. 2011090247 and OSSEOTITE® endosteal dental implant of Certain® 4x15 mm Parallel Walls with reference number IOSS415 and lot no. 2010121294

Según Agencia Española de Medicamentos y Productos Sanitarios (Via FOI), este evento ( retiro de equipo o alerta de seguridad ) involucró a un dispositivo médico en Spain que fue producido por Biomet 3i.

¿Qué es esto?

Las alertas proporcionan información importante y recomendaciones sobre los productos. Aunque se haya emitido una alerta, esto no significa necesariamente que el producto se considera peligroso. Las alertas de seguridad, dirigidas a trabajadores de la salud y a usuarios, pueden incluir retiro de equipos. Pueden ser escritas por los fabricantes, pero también por funcionarios del área de salud.

Más información acerca de la data acá
  • Tipo de evento
    Recall / Safety Alert
  • Fecha
    2013-07-09
  • País del evento
    Spain
  • Fuente del evento
    AEMPSVFOI
  • Notas / Alertas
    The data from Spain is current through June 2018. All of the data comes from Agencia Española de Medicamentos y Productos Sanitarios, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Spain.
  • Notas adicionales en la data
  • Acción
    Withdrawal from the market of certain batches of OSSEOTITE® endosseous dental implants, manufactured by Biomet 3i, USA

Device

OSSEOTITE® 2 Certain® PREVAIL® endosteal dental implant 5 X 4.1 X 11.5 mm with reference no. XIIO...

Manufacturer

Biomet 3i
  • Empresa matriz del fabricante (2017)
    Zimmer Biomet Holdings
  • Comentario del fabricante
    “The safety of patients has always been, and continues to be, Zimmer Biomet’s top priority and it is our honor to be a leader in this industry for the past 90 years,” Zimmer Biomet told ICIJ in a statement. “We adhere to strict regulatory standards, and work closely with the FDA and all applicable regulatory agencies in each of our regions as part of our commitment to operating a first-rate quality management system across our global manufacturing network. The company added that it is focused on staying at the forefront of innovation and doing right by the millions of patients who rely on the company’s products.
  • Source
    AEMPSVFOI